Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors
Abstract
:1. Introduction
2. Validation of CA IX/XII as Antitumor Drug Targets
3. Small Molecule CA IX/XII Inhibitors as Antitumor Agents
4. Antibodies Targeting CA IX and XII as Antitumor Agents
4.1. Anti-CA IX Antibodies
4.2. Anti-CA XII Antibodies
5. Imaging CA IX/XII Positive Tumors
6. Conclusions
Acknowledgments
Conflicts of Interest
References
- Warburg, O. On respiratory impairment in cancer cells. Science 1956, 124, 269–270. [Google Scholar] [PubMed]
- Schwartz, L.; Supuran, C.T.; Alfarouk, K.O. The Warburg effect and the hallmarks of cancer. Anticancer Agents Med. Chem. 2017, 17, 164–170. [Google Scholar] [CrossRef] [PubMed]
- Semenza, G.L. Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology. Trends Mol. Med. 2001, 7, 345–350. [Google Scholar] [CrossRef]
- Pouysségur, J.; Dayan, F.; Mazure, N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441, 437–443. [Google Scholar] [CrossRef] [PubMed]
- Hockel, M.; Vaupel, P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93, 266–276. [Google Scholar] [CrossRef] [PubMed]
- Kremer, G.; Pouysségur, J. Tumor cell metabolism: Cancer’s Achilles’ heel. Cancer Cell. 2008, 13, 472–482. [Google Scholar] [CrossRef] [PubMed]
- Supuran, C.T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 2008, 7, 168–181. [Google Scholar] [CrossRef] [PubMed]
- Neri, D.; Supuran, C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov. 2011, 10, 767–777. [Google Scholar] [CrossRef] [PubMed]
- Wykoff, C.C.; Beasley, N.J.; Watson, P.H.; Turner, K.J.; Pastorek, J.; Sibtain, A.; Wilson, G.D.; Turley, H.; Talks, K.L.; Maxwell, P.H.; et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60, 7075–7083. [Google Scholar] [PubMed]
- Pastorek, J.; Pastoreková, S.; Callebaut, I.; Mornon, J.P.; Zelník, V.; Opavský, R.; Zat’ovicová, M.; Liao, S.; Portetelle, D.; Stanbridge, E.J. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment. Oncogene 1994, 9, 2877–2888. [Google Scholar] [PubMed]
- Tureci, O.; Sahin, U.; Vollmar, E.; Siemer, S.; Göttert, E.; Seitz, G.; Parkkila, A.K.; Shah, G.N.; Grubb, J.H.; Pfreundschuh, M.; et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc. Natl. Acad. Sci. USA 1998, 95, 7608–7613. [Google Scholar] [CrossRef] [PubMed]
- Boron, W.F. Regulation of intracellular pH. Adv. Physiol. Educ. 2004, 28, 160–179. [Google Scholar] [CrossRef] [PubMed]
- Gatenby, R.A.; Gillies, R.J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer. 2008, 8, 56–61. [Google Scholar] [CrossRef] [PubMed]
- Gatenby, R.A.; Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer. 2004, 4, 891–899. [Google Scholar] [CrossRef] [PubMed]
- Fiaschi, T.; Giannoni, E.; Taddei, M.L.; Cirri, P.; Marini, A.; Pintus, G.; Nativi, C.; Richichi, B.; Scozzafava, A.; Carta, F.; et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013, 12, 1791–1801. [Google Scholar] [CrossRef] [PubMed]
- Parks, S.K.; Chiche, J.; Pouysségur, J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 2013, 13, 611–623. [Google Scholar] [CrossRef] [PubMed]
- Pettersen, E.O.; Ebbesen, P.; Gieling, R.G.; Williams, K.J.; Dubois, L.; Lambin, P.; Ward, C.; Meehan, J.; Kunkler, I.H.; Langdon, S.P.; et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J. Enzyme Inhib. Med. Chem. 2015, 30, 689–721. [Google Scholar] [CrossRef] [PubMed]
- Perez-Sayans, M.; Garcia-Garcia, A.; Scozzafava, A.; Supuran, C.T. Inhibition of V-ATPase and carbonic anhydrases as interference strategy with tumor acidification processes. Curr. Pharm. Des. 2012, 18, 1407–1413. [Google Scholar] [CrossRef] [PubMed]
- Alterio, V.; Di Fiore, A.; D’Ambrosio, K.; Supuran, C.T.; De Simone, G. Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms? Chem. Rev. 2012, 112, 4421–4468. [Google Scholar] [CrossRef] [PubMed]
- Supuran, C.T. Structure and function of carbonic anhydrases. Biochem. J. 2016, 473, 2023–2032. [Google Scholar] [CrossRef] [PubMed]
- De Milito, A.; Marino, M.L.; Fais, S. A rationale for the use of proton pump inhibitors as antineoplastic agents. Curr. Pharm. Des. 2012, 18, 1395–1406. [Google Scholar] [CrossRef] [PubMed]
- Lugini, L.; Federici, C.; Borghi, M.; Azzarito, T.; Marino, M.L.; Cesolini, A.; Spugnini, E.P.; Fais, S. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J. Enzyme Inhib. Med. Chem. 2016, 31, 538–545. [Google Scholar] [CrossRef] [PubMed]
- Federici, C.; Lugini, L.; Marino, M.L.; Carta, F.; Iessi, E.; Azzarito, T.; Supuran, C.T.; Fais, S. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J. Enzyme Inhib. Med. Chem. 2016, 31, 119–125. [Google Scholar] [CrossRef] [PubMed]
- Hilvo, M.; Baranauskiene, L.; Salzano, A.M.; Scaloni, A.; Matulis, D.; Innocenti, A.; Scozzafava, A.; Monti, S.M.; Di Fiore, A.; De Simone, G.; et al. Biochemical characterization of CA IX: One of the most active carbonic anhydrase isozymes. J. Biol. Chem. 2008, 283, 27799–27809. [Google Scholar] [CrossRef] [PubMed]
- Alterio, V.; Hilvo, M.; Di Fiore, A.; Supuran, C.T.; Pan, P.; Parkkila, S.; Scaloni, A.; Pastorek, J.; Pastorekova, S.; Pedone, C.; et al. Crystal structure of the extracellular catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc. Natl. Acad. Sci. USA 2009, 106, 16233–16238. [Google Scholar] [CrossRef] [PubMed]
- Innocenti, A.; Pastorekova, S.; Pastorek, J.; Scozzafava, A.; De Simone, G.; Supuran, C.T. The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as an intrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors. Bioorg. Med. Chem. Lett. 2009, 19, 5825–5828. [Google Scholar] [CrossRef] [PubMed]
- Pastorek, J.; Pastorekova, S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use. Semin. Cancer Biol. 2015, 31, 52–64. [Google Scholar] [CrossRef] [PubMed]
- Svastová, E.; Zilka, N.; Zat’ovicová, M.; Gibadulinová, A.; Ciampor, F.; Pastorek, J.; Pastoreková, S. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp. Cell Res. 2003, 290, 332–345. [Google Scholar] [CrossRef]
- Svastová, E.; Hulíková, A.; Rafajová, M.; Zat’ovicová, M.; Gibadulinová, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C.T.; Pastorek, J.; et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577, 439–445. [Google Scholar] [CrossRef] [PubMed]
- Ditte, P.; Dequiedt, F.; Svastova, E.; Hulikova, A.; Ohradanova-Repic, A.; Zatovicova, M.; Csaderova, L.; Kopacek, J.; Supuran, C.T.; Pastorekova, S.; et al. Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res. 2011, 71, 7558–7567. [Google Scholar] [CrossRef] [PubMed]
- Buanne, P.; Renzone, G.; Monteleone, F.; Vitale, M.; Monti, S.M.; Sandomenico, A.; Garbi, C.; Montanaro, D.; Accardo, M.; Troncone, G.; et al. Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells. J. Proteome Res. 2013, 12, 282–292. [Google Scholar] [CrossRef] [PubMed]
- Buonanno, M.; Langella, E.; Zambrano, N.; Succoio, M.; Sasso, E.; Alterio, V.; Di Fiore, A.; Sandomenico, A.; Supuran, C.T.; Scaloni, A.; et al. Disclosing the interaction of carbonic anhydrase IX with cullin-associated NEDD8-dissociated protein 1 by molecular modeling and integrated binding measurements. ACS Chem. Biol. 2017, 12, 1460–1465. [Google Scholar] [CrossRef] [PubMed]
- Vullo, D.; Innocenti, A.; Nishimori, I.; Pastorek, J.; Scozzafava, A.; Pastoreková, S.; Supuran, C.T. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs? Bioorg. Med. Chem. Lett. 2005, 15, 963–969. [Google Scholar] [CrossRef] [PubMed]
- Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C.T. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2003, 13, 1005–1009. [Google Scholar] [CrossRef]
- Guler, O.O.; De Simone, G.; Supuran, C.T. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr. Med. Chem. 2010, 17, 1516–1526. [Google Scholar] [CrossRef] [PubMed]
- Supuran, C.T. How many carbonic anhydrase inhibition mechanisms exist? J. Enzyme Inhib. Med. Chem. 2016, 31, 345–360. [Google Scholar] [CrossRef] [PubMed]
- Supuran, C.T. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin. Drug Discov. 2017, 12, 61–88. [Google Scholar] [CrossRef] [PubMed]
- Supuran, C.T. Structure-based drug discovery of carbonic anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 2012, 27, 759–772. [Google Scholar] [CrossRef] [PubMed]
- Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastoreková, S.; Scozzafava, A.; Winum, J.Y.; Montero, J.L.; Supuran, C.T. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J. Med. Chem. 2005, 48, 4834–4841. [Google Scholar] [CrossRef] [PubMed]
- Dubois, L.; Douma, K.; Supuran, C.T.; Chiu, R.K.; van Zandvoort, M.A.; Pastoreková, S.; Scozzafava, A.; Wouters, B.G.; Lambin, P. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother. Oncol. 2007, 83, 367–373. [Google Scholar] [CrossRef] [PubMed]
- Dubois, L.; Lieuwes, N.G.; Maresca, A.; Thiry, A.; Supuran, C.T.; Scozzafava, A.; Wouters, B.G.; Lambin, P. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother. Oncol. 2009, 92, 423–428. [Google Scholar] [CrossRef] [PubMed]
- Ahlskog, J.K.; Dumelin, C.E.; Trüssel, S.; Mårlind, J.; Neri, D. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg. Med. Chem. Lett. 2009, 19, 4851–4856. [Google Scholar] [CrossRef] [PubMed]
- Dubois, L.; Peeters, S.; Lieuwes, N.G.; Geusens, N.; Thiry, A.; Wigfield, S.; Carta, F.; McIntyre, A.; Scozzafava, A.; Dogné, J.M.; et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother. Oncol. 2011, 99, 424–431. [Google Scholar] [CrossRef] [PubMed]
- Lou, Y.; McDonald, P.C.; Oloumi, A.; Chia, S.; Ostlund, C.; Ahmadi, A.; Kyle, A.; Auf dem Keller, U.; Leung, S.; Huntsman, D.; et al. Targeting tumor hypoxia: Suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011, 71, 3364–3376. [Google Scholar] [CrossRef] [PubMed]
- Pacchiano, F.; Carta, F.; McDonald, P.C.; Lou, Y.; Vullo, D.; Scozzafava, A.; Dedhar, S.; Supuran, C.T. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. Med. Chem. 2011, 54, 1896–1902. [Google Scholar] [CrossRef] [PubMed]
- Gieling, R.G.; Babur, M.; Mamnani, L.; Burrows, N.; Telfer, B.A.; Carta, F.; Winum, J.Y.; Scozzafava, A.; Supuran, C.T.; Williams, K.J. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J. Med. Chem. 2012, 55, 5591–5600. [Google Scholar] [CrossRef] [PubMed]
- Touisni, N.; Maresca, A.; McDonald, P.C.; Lou, Y.; Scozzafava, A.; Dedhar, S.; Winum, J.Y.; Supuran, C.T. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J. Med. Chem. 2011, 54, 8271–8277. [Google Scholar] [CrossRef] [PubMed]
- Lock, F.E.; McDonald, P.C.; Lou, Y.; Serrano, I.; Chafe, S.C.; Ostlund, C.; Aparicio, S.; Winum, J.Y.; Supuran, C.T.; Dedhar, S. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013, 32, 5210–5219. [Google Scholar] [CrossRef] [PubMed]
- McDonald, P.C.; Chafe, S.C.; Dedhar, S. Overcoming hypoxia-mediated tumor progression: combinatorial approaches targeting ph regulation, angiogenesis and immune dysfunction. Front. Cell Dev. Biol. 2016, 4, 27. [Google Scholar] [CrossRef] [PubMed]
- Swayampakula, M.; McDonald, P.C.; Vallejo, M.; Coyaud, E.; Chafe, S.C.; Westerback, A.; Venkateswaran, G.; Shankar, J.; Gao, G.; Laurent, E.M.N.; et al. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene. 2017, in press. [Google Scholar] [CrossRef] [PubMed]
- A phase I, multi-center, open-label, study to investigate the safety, tolerability and pharmacokinetic of SLC-0111 in subjects with advanced solid tumours. 2016. Available online: https://clinicaltrials.gov/ct2/show/NCT02215850 (accessed on 15 September 2017).
- Pacchiano, F.; Aggarwal, M.; Avvaru, B.S.; Robbins, A.H.; Scozzafava, A.; McKenna, R.; Supuran, C.T. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem. Commun. 2010, 46, 8371–8373. [Google Scholar] [CrossRef] [PubMed]
- Perut, F.; Carta, F.; Bonuccelli, G.; Grisendi, G.; Di Pompo, G.; Avnet, S.; Sbrana, F.V.; Hosogi, S.; Dominici, M.; Kusuzaki, K.; et al. Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment. Expert Opin. Ther. Targets. 2015, 19, 1593–1605. [Google Scholar] [CrossRef] [PubMed]
- Logsdon, D.P.; Grimard, M.; Luo, M.; Shahda, S.; Jiang, Y.; Tong, Y.; Yu, Z.; Zyromski, N.; Schipani, E.; Carta, F.; et al. Regulation of HIF1α under hypoxia by APE1/Ref-1 impacts CA9 expression: Dual targeting in patient-derived 3D pancreatic cancer models. Mol. Cancer Ther. 2016, 15, 2722–2732. [Google Scholar] [CrossRef] [PubMed]
- Krall, N.; Pretto, F.; Decurtins, W.; Bernardes, G.J.; Supuran, C.T.; Neri, D. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew. Chem. Int. Ed. Engl. 2014, 53, 4231–4235. [Google Scholar] [CrossRef] [PubMed]
- Grabmaier, K.; Vissers, J.L.; De Weijert, M.C.; Oosterwijk-Wakka, J.C.; Van Bokhoven, A.; Brakenhoff, R.H.; Noessner, E.; Mulders, P.A.; Merkx, G.; Figdor, C.G.; et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int. J. Cancer 2000, 85, 865–870. [Google Scholar] [CrossRef]
- Siebels, M.; Rohrmann, K.; Oberneder, R.; Stahler, M.; Haseke, N.; Beck, J.; Hofmann, R.; Kindler, M.; Kloepfer, P.; Stief, C. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J. Urol. 2011, 29, 121–126. [Google Scholar] [CrossRef] [PubMed]
- A Randomized, Double Blind Phase III Study to Evaluate Adjuvant cG250 Treatment Versus Placebo in Patients with Clear Cell RCC and High Risk of Recurrence (ARISER). Available online: https://clinicaltrials.gov/ct2/show/NCT00087022?term=girentuximab&rank=6 (accessed on 15 September 2017).
- Takacova, M.; Hlouskova, G.; Zatovicova, M.; Benej, M.; Sedlakova, O.; Kopacek, J.; Pastorek, J.; Lacik, I.; Pastorekova, S. Encapsulation of anti-carbonic anhydrase IX antibody in hydrogel microspheres for tumor targeting. J. Enzyme Inhib. Med. Chem. 2016, 31, 110–118. [Google Scholar] [CrossRef] [PubMed]
- Zatovicova, M.; Jelenska, L.; Hulikova, A.; Csaderova, L.; Ditte, Z.; Ditte, P.; Goliasova, T.; Pastorek, J.; Pastorekova, S. Carbonic anhydrase IX as an anticancer therapy target: Preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr. Pharm. Des. 2010, 16, 3255–3263. [Google Scholar] [CrossRef] [PubMed]
- Battke, C.; Kremmer, E.; Mysliwietz, J.; Gondi, G.; Dumitru, C.; Brandau, S.; Lang, S.; Vullo, D.; Supuran, C.; Zeidler, R. Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol. Immunother. 2011, 60, 649–658. [Google Scholar] [CrossRef] [PubMed]
- Gondi, G.; Mysliwietz, J.; Hulikova, A.; Jen, J.P.; Swietach, P.; Kremmer, E.; Zeidler, R. Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res. 2013, 73, 6494–6503. [Google Scholar] [CrossRef] [PubMed]
- Akurathi, V.; Dubois, L.; Lieuwes, N.G.; Chitneni, S.K.; Cleynhens, B.J.; Vullo, D.; Supuran, C.T.; Verbruggen, A.M.; Lambin, P.; Bormans, G.M. Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. Nucl. Med. Biol. 2010, 37, 557–564. [Google Scholar] [CrossRef] [PubMed]
- Akurathi, V.; Dubois, L.; Celen, S.; Lieuwes, N.G.; Chitneni, S.K.; Cleynhens, B.J.; Innocenti, A.; Supuran, C.T.; Verbruggen, A.M.; Lambin, P.; et al. Development and biological evaluation of 99mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers. Eur. J. Med. Chem. 2014, 71, 374–384. [Google Scholar] [CrossRef] [PubMed]
- Peeters, S.G.; Dubois, L.; Lieuwes, N.G.; Laan, D.; Mooijer, M.; Schuit, R.C.; Vullo, D.; Supuran, C.T.; Eriksson, J.; Windhorst, A.D.; et al. [18F]VM4–o37 MicroPET imaging and biodistribution of two in vivo CAIX-expressing tumor models. Mol. Imaging Biol. 2015, 17, 615–619. [Google Scholar] [CrossRef] [PubMed]
- Pan, J.; Lau, J.; Mesak, F.; Hundal, N.; Pourghiasian, M.; Liu, Z.; Bénard, F.; Dedhar, S.; Supuran, C.T.; Lin, K.S. Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. J. Enzyme Inhib. Med. Chem. 2014, 29, 249–255. [Google Scholar] [CrossRef] [PubMed]
- Lau, J.; Liu, Z.; Lin, K.S.; Pan, J.; Zhang, Z.; Vullo, D.; Supuran, C.T.; Perrin, D.M.; Bénard, F. Trimeric radiofluorinated sulfonamide derivatives to achieve in vivo selectivity for carbonic anhydrase IX-targeted PET imaging. J. Nucl. Med. 2015, 56, 1434–1440. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Lau, J.; Zhang, C.; Colpo, N.; Nocentini, A.; Supuran, C.T.; Bénard, F.; Lin, K.S. Design, synthesis and evaluation of 18F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging. J. Enzyme Inhib. Med. Chem. 2017, 32, 722–730. [Google Scholar] [CrossRef] [PubMed]
- Lau, J.; Zhang, Z.; Jenni, S.; Kuo, H.T.; Liu, Z.; Vullo, D.; Supuran, C.T.; Lin, K.S.; Bénard, F. PET imaging of carbonic anhydrase IX expression of HT-29 tumor xenograft mice with 68Ga-labeled benzenesulfonamides. Mol. Pharm. 2016, 13, 1137–1146. [Google Scholar] [CrossRef] [PubMed]
- Sneddon, D.; Niemans, R.; Bauwens, M.; Yaromina, A.; van Kuijk, S.J.; Lieuwes, N.G.; Biemans, R.; Pooters, I.; Pellegrini, P.A.; Lengkeek, N.A.; et al. Synthesis and in vivo biological evaluation of 68Ga-labeled carbonic anhydrase IX targeting small molecules for positron emission tomography. J. Med. Chem. 2016, 59, 6431–6443. [Google Scholar] [CrossRef] [PubMed]
- Ahlskog, J.K.; Schliemann, C.; Mårlind, J.; Qureshi, U.; Ammar, A.; Pedley, R.B.; Neri, D. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br. J. Cancer. 2009, 101, 645–657. [Google Scholar] [CrossRef] [PubMed]
- Huizing, F.J.; Hoeben, B.A.W.; Franssen, G.; Lok, J.; Heskamp, S.; Oosterwijk, E.; Boerman, O.C.; Bussink, J. Preclinical validation of 111In-girentuximab-F(ab′)2 as a tracer to image hypoxia related marker CA IX expression in head and neck cancer xenografts. Radiother Oncol. 2017, in press. [Google Scholar] [CrossRef]
- Honarvar, H.; Garousi, J.; Gunneriusson, E.; Höidén-Guthenberg, I.; Altai, M.; Widström, C.; Tolmachev, V.; Frejd, F.Y. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX: 1 affibody molecule. Int. J. Oncol. 2015, 46, 513–520. [Google Scholar] [CrossRef] [PubMed]
- Khandani, A.H.; Rathmell, W.K.; Wallen, E.M.; Ivanovic, M. PET/CT with 124I-cG250: Great potential and some open questions. AJR Am. J. Roentgenol. 2014, 203, 261–262. [Google Scholar] [CrossRef] [PubMed]
- Muselaers, C.H.; Rijpkema, M.; Bos, D.L.; Langenhuijsen, J.F.; Oyen, W.J.; Mulders, P.F.; Oosterwijk, E.; Boerman, O.C. Radionuclide and fluorescence imaging of clear cell renal cell carcinoma using dual labeled anti-carbonic anhydrase IX antibody G250. J. Urol. 2015, 194, 532–538. [Google Scholar] [CrossRef] [PubMed]
© 2017 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Supuran, C.T. Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors. Metabolites 2017, 7, 48. https://doi.org/10.3390/metabo7030048
Supuran CT. Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors. Metabolites. 2017; 7(3):48. https://doi.org/10.3390/metabo7030048
Chicago/Turabian StyleSupuran, Claudiu T. 2017. "Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors" Metabolites 7, no. 3: 48. https://doi.org/10.3390/metabo7030048